156 related articles for article (PubMed ID: 32556947)
21. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation.
Howard DH; Tangka FK; Guy GP; Ekwueme DU; Lipscomb J
Health Aff (Millwood); 2013 Mar; 32(3):596-602. PubMed ID: 23459740
[TBL] [Abstract][Full Text] [Related]
22. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S; Sharma KP; Fan L; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
[TBL] [Abstract][Full Text] [Related]
23. Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
Nguyen DD; Trinh QD; Cole AP; Kilbridge KL; Mahal BA; Hayn M; Hansen M; Han PKJ; Sammon JD
Cancer; 2021 Jan; 127(2):249-256. PubMed ID: 33165954
[TBL] [Abstract][Full Text] [Related]
24. Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic.
Qian Z; Chen X; Cole AP; Abdollah F; Choueiri TK; Kibel AS; Lipsitz SR; Iyer HS; Trinh QD
Eur Urol Oncol; 2024 Feb; 7(1):151-154. PubMed ID: 37487814
[TBL] [Abstract][Full Text] [Related]
25. Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations.
Rahbar H; Karabon P; Menon M; Trinh QD; Abdollah F
Eur Urol Focus; 2018 Dec; 4(6):1002-1004. PubMed ID: 28753856
[TBL] [Abstract][Full Text] [Related]
26. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.
Kensler KH; Pernar CH; Mahal BA; Nguyen PL; Trinh QD; Kibel AS; Rebbeck TR
J Natl Cancer Inst; 2021 Jun; 113(6):719-726. PubMed ID: 33146392
[TBL] [Abstract][Full Text] [Related]
27. Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses.
Dalela D; Sun M; Diaz M; Karabon P; Seisen T; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2019 Jan; 5(1):77-80. PubMed ID: 28753893
[TBL] [Abstract][Full Text] [Related]
28. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
[TBL] [Abstract][Full Text] [Related]
29. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
30. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.
Goodwin JS; Jaramillo E; Yang L; Kuo YF; Tan A
PLoS One; 2014; 9(9):e107352. PubMed ID: 25208250
[TBL] [Abstract][Full Text] [Related]
31. Increasing aggressive prostate cancer.
Shah N; Ioffe V; Chang JC
Can J Urol; 2022 Dec; 29(6):11384-11390. PubMed ID: 36495581
[TBL] [Abstract][Full Text] [Related]
32. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
Fleshner K; Carlsson SV; Roobol MJ
Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937
[TBL] [Abstract][Full Text] [Related]
33. The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
Becker DJ; Rude T; Walter D; Wang C; Loeb S; Li H; Ciprut S; Kelly M; Zeliadt SB; Fagerlin A; Lepor H; Sherman S; Ravenell JE; Makarov DV
J Natl Cancer Inst; 2021 May; 113(5):626-631. PubMed ID: 32797212
[TBL] [Abstract][Full Text] [Related]
34. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
35. Investigating the racial gap in prostate cancer screening with prostate-specific antigen among younger men from 2012 to 2020.
Qian Z; Al Khatib K; Chen X; Belani S; Labban M; Lipsitz S; Cole AP; Iyer HS; Trinh QD
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36708009
[TBL] [Abstract][Full Text] [Related]
36. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
37. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
38. Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.
Johnson JA; Moser RP; Ellison GL; Martin DN
J Community Health; 2021 Apr; 46(2):389-398. PubMed ID: 33064229
[TBL] [Abstract][Full Text] [Related]
39. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
Lai SM; Keighley J; Garimella S; Enko M; Parker WP
JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
[TBL] [Abstract][Full Text] [Related]
40. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
